Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Safello - Navigating a critical crossroads

Safello Group

Redeye notes Safello’s headwinds from Q1 continued into Q2 2025, with net sales disappointing, resulting in an adjusted EBITDA loss of SEK4.9m. According to management, a trend shift has been noted in Q3, supported by altcoin activity. Redeye believes Safello needs to successfully launch its Atoma and ETP offering to return to profitability in the near term as OPEX continues to be burdened by MiCA-related costs. However, the targets around these remain nebulous. Turnaround in engagement metrics and granting of a MiCA license are key catalysts. Redeye reduces its estimates and fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Safello - Navigating a critical crossroads

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.